Işıl Çakmak KARAER, Ayla ÇİMEN ÖZAYDOĞDU

Effect of montelukast treatment on adenoid hypertrophy and sleep quality in pediatric patients

Adenoid vegetation is part of lymphoid tissue located in the upper respiratory tract. When adenoid tissue becomes hypertrophied, it may cause narrowing of the respiratory tract and complications. Generally, treatment of adenoid hypertrophy is surgical; however, currently reducing the size of adenoid hypertrophy with the leukotriene receptor blocker of montelukast is evaluated among treatment choices apart from surgery. The aim of the study was to assess whether montelukast treatment is an alternative to surgical treatment or not. The study included a total of 50 pediatric patients. Adenoid tissue size was evaluated endoscopically and radiographically. Patients were divided into two groups based on closure of the nasopharynx by adenoid tissue. Group 1 comprised adenoid hypertrophy cases with the choana blocked by less than 50%, with Group 2 comprising children with adenoid hypertrophy and more than 50% closure of the choana. All patients began 5 mg montelukast treatment for 12 weeks. Patients had the pediatric sleep questionnaire applied before and after treatment. Tests and radiographic results were compared. In both groups, it was identified that montelukast treatment had no effect on adenoid tissue size (p=0.286, 0.304, respectively). Contrary to this, patients in Group 1 were identified to have statistically significant improvement in sleep quality with montelukast treatment (p=0.006). In Group 2 patients, there was no such improvement in sleep quality identified (p=0.91). Montelukast treatment increased sleep quality in children with less than 50% obstruction of the choana.

PDF

___

1. Mnatsakanian A, Sharma S. Anatomy , Head and Neck, Adenoids. Treasure Island (FL). SourceStatPearls, StatPearls Publishing; 2019.

2. Scadding G. Non-surgical treatment of adenoidal hypertrophy: the role of treating IgE-mediated inflammation. Pediatr Allergy Immunol. 2010;21:1095–106.

3. Major MP, Flores-Mir C, Major PW. Assessment of lateral cephalometric diagnosis of adenoid hypertrophy and posterior upper airway obstruction: a systematic review. Am J Orthod Dentofac Orthop. 2006;130:700–8.

4. Caylakli F, Hizal E, Yilmaz I ,et al. Correlation between adenoidnasopharynx ratio and endoscopic examination of adenoid hypertrophy: a blind, prospective clinical study. Int J Pediatr Otorhinolaryngol. 2009;73:1532-5.

5. Benjamin JM, Gunjan G. Adenoidectomy. Treasure Island (FL). StatPearls Publishing; 2020.6. National Heart, Lung, and Blood Institute. National asthma education and prevention program; expert panel report 3: guidelines for the diagnosis and management of asthma. 2007.

6. Berlucchi M, Salsi D, Valetti L, et al. The role of montelukast in the treatment of adenoidal hypertrophy in the pediatric age group: preliminary results of a prospective, randomized study. Pediatrics 2007;119:1392–7.

7. Goldbart AD, Goldman GL, Li RC, Brittian KR, et al. Differential expression of cysteinyl leukotriene receptors 1 and 2 in tonsils of children with obstructive sleep apnea and recurrent infection. Chest. 2004;126:13–8.

8. Goldbart AD, Greenberg-Dotan S, Tal A. Montelukast for children with obstructive sleep apnea: a double-blind, placebo controlled study. Pediatrics 2012;130:575-80.

9. Shokouhi F, Jahromi AM, Majidi MR, et al. Montelukast in adenoid hypertrophy: its effect on size and symptoms. Iranian Journal of Otorhinolaryngology. 2015;27:443-8.

10. Cassano P, Gelardi M, Cassano M, et al. Adenoid tissue rhinopharyngeal obstruction grading based on fiberendoscopic findings: a novel approach to therapeutic management. Int J Pediatr Otorhinolaryngol. 2003;67:1303-9.

11. Fujioka M, Young LW, Girdany BR. Radiographic evaluation of adenoidal size in children: adenoidal-nasopharyngeal ratio. AJR Am J Roentgenol. 1979;133:401–4.

12. Yuksel H, Sogut A, Yılmaz O, et al. Reliability and validity of the Turkish version of the pediatric sleep questionnaire: a tool for prediction of sleep related breathing disorder. Tüberküloz ve Toraks Dergisi. 2011;59:236-41.

13. Tuhanıoğlu B, Erkan SO. Evaluation of the effects of montelukast, mometasone furoate, and combined therapyon adenoid size: a randomized, prospective, clinical trial with objective data. Turk J Med Sci. 2017;47:1736- 43.

14. Goldbart AD, Goldman JL, Veling MC, et al.Leukotriene Modifier Therapy for Mild Sleep-disordered Breathing in Children. Am J Respir Crit Care Med. 2005; 172:64-370.

15. Dayyat E, Serpero LD, Kheirandish-Gozal L, et al.Leukotriene Pathways and In Vitro Adenotonsillar Cell Proliferation in Children With Obstructive Sleep Apnea Chest. 2009;135:1142-9.

16. Kumar J. Clinical Outcomes of Montelukast Sodium in Children with Adenoid Hypertrophy. Biomed J Sci & Tech Res 27-2020. BJSTR. MS.ID.004438.

17. Kheirandish-Gozal L, Bandla H. P. R, Gozal D. Montelukast for Children with Obstructive Sleep Apnea: Results of a Double-Blind, Randomized, Placebo-Controlled Trial. Ann Am Thorac Soc. 2016;13:1736–41.

18. Kar M, Altıntoprak N, Muluk BN, et al. Antileukotrienes in adenotonsillar hypertrophy: a review of the literature. European Archives of Oto-Rhino- Laryngology. 2016;273:4111–7.